title: Forging a link between oncogenic signaling and immunosuppression in melanoma.
abstract: Immunosuppressive tumor microenvironments limit the efficacy of T cell-based immunotherapy. We have recently demonstrated that the inhibition of BRAFV600Ewith vemurafenib relieves interleukin-1 (IL-1)-induced T-cell suppression as mediated by melanoma tumor associated fibroblasts (TAFs). These results suggest that inhibitors of the MAPK pathway in combination with T cell-based immunotherapies may induce long-lasting and durable responses.
authors.affiliation: Department of Melanoma Medical Oncology; The Center for Cancer Immunology Research; The University of Texas MD Anderson Cancer Center; Houston, TX USA.
authors.forename: Jahan S
authors.initials: JS
authors.lastname: Khalili
authors.forename: Patrick
authors.initials: P
authors.lastname: Hwu
authors.forename: Gregory
authors.initials: G
authors.lastname: Lizée
keywords: BRAF; COX-2; PD-1 ligands; cytotoxic T cells; immune suppression; interleukin-1; tumor-associated fibroblasts